Unknown

Dataset Information

0

A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.


ABSTRACT: We have developed a theranostic nanoparticle delivering the model radionuclide (177)Lu based on the versatile lipid-calcium-phosphate (LCP) nanoparticle delivery platform. Characterization of (177)Lu-LCP has shown that radionuclide loading can be increased by several orders of magnitude without affecting the encapsulation efficiency or the morphology of (177)Lu-LCP, allowing consistency during fabrication and overcoming scale-up barriers typical of nanotherapeutics. The choice of (177)Lu as a model radionuclide has allowed in vivo anticancer therapy in addition to radiographic imaging via the dual decay modes of (177)Lu. Tumor accumulation of (177)Lu-LCP was measured using both SPECT and Cerenkov imaging modalities in live mice, and treatment with just one dose of (177)Lu-LCP showed significant in vivo tumor inhibition in two subcutaneous xenograft tumor models. Microenvironment and cytotoxicity studies suggest that (177)Lu-LCP inhibits tumor growth by causing apoptotic cell death via double-stranded DNA breaks while causing a remodeling of the tumor microenvironment to a more disordered and less malignant phenotype.

SUBMITTER: Satterlee AB 

PROVIDER: S-EPMC4640695 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.

Satterlee Andrew B AB   Yuan Hong H   Huang Leaf L  

Journal of controlled release : official journal of the Controlled Release Society 20150901


We have developed a theranostic nanoparticle delivering the model radionuclide (177)Lu based on the versatile lipid-calcium-phosphate (LCP) nanoparticle delivery platform. Characterization of (177)Lu-LCP has shown that radionuclide loading can be increased by several orders of magnitude without affecting the encapsulation efficiency or the morphology of (177)Lu-LCP, allowing consistency during fabrication and overcoming scale-up barriers typical of nanotherapeutics. The choice of (177)Lu as a mo  ...[more]

Similar Datasets

| S-EPMC9881475 | biostudies-literature
| S-EPMC3198802 | biostudies-literature
| S-EPMC3373296 | biostudies-literature
| S-EPMC5334464 | biostudies-literature
| S-EPMC5535907 | biostudies-other
| S-EPMC7922065 | biostudies-literature
| S-EPMC4426239 | biostudies-literature
| S-EPMC7904601 | biostudies-literature
| S-EPMC6289590 | biostudies-literature
| S-EPMC8625430 | biostudies-literature